Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.
about
Bevacizumab in the treatment of NSCLC: patient selection and perspectives.Newly developed anti-angiogenic therapy in non-small cell lung cancer.Anti-angiogenic therapies in brain metastases.PET-CT evaluation of the curative effect of crizotinib on malignant myofibroblastoma with rare mutation of ALK R401: a case report and literature review.
P2860
Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@en
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@nl
type
label
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@en
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@nl
prefLabel
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@en
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@nl
P2093
P2860
P356
P1433
P1476
Bevacizumab, pemetrexed and ca ...... atients with brain metastases.
@en
P2093
Alexandros Ardavanis
Antigoni Sakellaropoulou
Despina Gkeka
Dimitra Stefanou
Gavriil Akakios
Maria Prevezanou
Marina Gkiaouraki
Sofia Stamatopoulou
P2860
P304
P356
10.3892/OL.2016.5268
P577
2016-10-17T00:00:00Z